These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34566919)

  • 1. Prudent Use of Tylosin for Treatment of
    Huang A; Wang S; Guo J; Gu Y; Li J; Huang L; Wang X; Tao Y; Liu Z; Yuan Z; Hao H
    Front Microbiol; 2021; 12():712473. PubMed ID: 34566919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational Use of Danofloxacin for Treatment of
    Wang S; Huang A; Gu Y; Li J; Huang L; Wang X; Tao Y; Liu Z; Wu C; Yuan Z; Hao H
    Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Tylosin and Tilmicosin Against Experimental
    Garmyn A; Vereecken M; De Gussem K; Depondt W; Haesebrouck F; Martel A
    Avian Dis; 2019 Jun; 63(2):359-365. PubMed ID: 31251538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Regimens and Clinical Breakpoint of Avilamycin Against
    Huang A; Luo X; Xu Z; Huang L; Wang X; Xie S; Pan Y; Fang S; Liu Z; Yuan Z; Hao H
    Front Pharmacol; 2022; 13():769539. PubMed ID: 35281904
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Huang Z; Wu Y; Zhou Z; Xia X; Gu X; Cai Q; Shen X; Yang H; Ding H
    Front Pharmacol; 2019; 10():670. PubMed ID: 31293418
    [No Abstract]   [Full Text] [Related]  

  • 6. Exploration of Clinical Breakpoint of Danofloxacin for
    Xu Z; Huang A; Luo X; Zhang P; Huang L; Wang X; Mi K; Fang S; Huang X; Li J; Yuan Z; Hao H
    Antibiotics (Basel); 2021 Jul; 10(7):. PubMed ID: 34356730
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Breakpoint of Apramycin to Swine
    Dai X; Gu Y; Guo J; Huang L; Cheng G; Peng D; Hao H
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The minimum inhibitory concentration of tilmicosin and tylosin for mycoplasma gallisepticum and Mycoplasma synoviae and a comparison of their efficacy in the control of Mycoplasma gallisepticum infection in broiler chicks.
    Jordan FT; Horrocks BK
    Avian Dis; 1996; 40(2):326-34. PubMed ID: 8790882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs.
    Huang L; Zhang H; Li M; Ahmad I; Wang Y; Yuan Z
    BMC Vet Res; 2018 Oct; 14(1):319. PubMed ID: 30355326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Profiles of Tiamulin in an Experimental Intratracheal Infection Model of Mycoplasma gallisepticum.
    Xiao X; Sun J; Yang T; Fang X; Cheng J; Xiong YQ; Liu YH
    Front Vet Sci; 2016; 3():75. PubMed ID: 27656647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China.
    Mi K; Sun D; Li M; Hao H; Zhou K; Liu Z; Yuan Z; Huang L
    Pathogens; 2021 Jan; 10(2):. PubMed ID: 33498972
    [No Abstract]   [Full Text] [Related]  

  • 12. Ex vivo pharmacokinetic and pharmacodynamic analysis of valnemulin against Mycoplasma gallisepticum S6 in Mycoplasma gallisepticum and Escherichia coli co-infected chickens.
    Xiao X; Sun J; Chen Y; Zou M; Zhao DH; Liu YH
    Vet J; 2015 Apr; 204(1):54-9. PubMed ID: 25744809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PK-PD Relationship and Resistance Development of Danofloxacin against
    Zhang N; Wu Y; Huang Z; Yao L; Zhang L; Cai Q; Shen X; Jiang H; Ding H
    Front Microbiol; 2017; 8():926. PubMed ID: 28611739
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic integration of tilmicosin against
    Zhang N; Zhou M; Yan X; Liu J; Yuan S; Yang H; Ding H; Zhang D; Bai Y
    Front Vet Sci; 2022; 9():952599. PubMed ID: 36246335
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the pharmacokinetics of tilmicosin in plasma and lung tissue in healthy chickens and chickens experimentally infected with Mycoplasma gallisepticum.
    Zhang N; Liu Z; Wei Y; Zhang C; Mao C; Cai Q; Shen X; Ding H
    J Vet Pharmacol Ther; 2020 Jul; 43(4):347-354. PubMed ID: 32133660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo comparisons of valnemulin, tiamulin, tylosin, enrofloxacin, and lincomycin/spectinomycin against Mycoplasma gallisepticum.
    Jordan FT; Forrester CA; Ripley PH; Burch DG
    Avian Dis; 1998; 42(4):738-45. PubMed ID: 9876842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal Regimens and Cutoff Evaluation of Tildipirosin Against
    Lei Z; Liu Q; Qi Y; Yang B; Khaliq H; Xiong J; Moku GK; Ahmed S; Li K; Zhang H; Zhang W; Cao J; He Q
    Front Pharmacol; 2018; 9():765. PubMed ID: 30093860
    [No Abstract]   [Full Text] [Related]  

  • 18. Field evaluation of tylosin premix in layers previously vaccinated with a live Mycoplasma gallisepticum vaccine.
    Evans RD; Trites JD; Cochrane RL
    Avian Dis; 2002; 46(1):208-14. PubMed ID: 11922337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of Susceptibility Breakpoint for Cefquinome against
    Mi K; Li M; Sun L; Hou Y; Zhou K; Hao H; Pan Y; Liu Z; Xie C; Huang L
    Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34439008
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro activity of danofloxacin, tylosin and oxytetracycline against mycoplasmas of veterinary importance.
    Cooper AC; Fuller JR; Fuller MK; Whittlestone P; Wise DR
    Res Vet Sci; 1993 May; 54(3):329-34. PubMed ID: 8393208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.